Results 81 to 90 of about 53,372 (96)

The chemokine receptor antagonist, TAK‐779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function

British Journal of Pharmacology, 2009
Jia Ni, Yi-na Zhu, Xiang-Gen Zhong, Yu Ding, Li-fei Hou, Xiankun Tong, Wei Tang, S. Ono, Yi-fu Yang, Jian-Ping Zuo   +9 more
semanticscholar   +1 more source

Editorial

Therapeutic Advances in Respiratory Disease, 2007
Mario Cazzola
doaj   +1 more source

Some of the next articles are maybe not open access.

Related searches:

“It Is Better If I Kill Her”: Perceptions and Opinions of Violence Against Women and Femicide in Ocotal, Nicaragua, After Law 779

, 2015
The objective of this research is to examine women's perceptions and opinions of violence against women (VAW) and femicide in Ocotal, Nicaragua, since the introduction of Law 779, a national law implemented in 2012 meant to eradicate VAW.
M. LuffySamantha, P. EvansDabney, W. RochatRoger   +2 more
semanticscholar   +1 more source

Diverse modifications of the 4-methylphenyl moiety of TAK-779 by late-stage Suzuki-Miyaura cross-coupling.

Organic and biomolecular chemistry, 2014
Chemokine receptor 5 (CCR5) antagonists provide a new therapeutic approach in the treatment of HIV-1 (AIDS). TAK-779 displays high affinity and selectivity for the CCR5 receptor and serves as a lead compound for the development of further antagonists. In
Anna Junker, D. Schepmann, Junichiro Yamaguchi, K. Itami, A. Faust, K. Kopka, S. Wagner, B. Wünsch   +7 more
semanticscholar   +1 more source

Synthesis of thiophene-based TAK-779 analogues by C-H arylation.

Journal of Organic Chemistry, 2013
A rapid synthesis of thiophene-based TAK-779 analogues 1 is reported using a late-stage diversification strategy. At the end of the synthesis, the key building block 2, which was prepared in six steps from thiophene, was arylated regioselectively at the ...
Anna Junker, Junichiro Yamaguchi, K. Itami, B. Wünsch   +3 more
semanticscholar   +1 more source

Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.

, 2014
Background: Preclinical data indicate activity of mammalian target of rapamycin inhibitors and synergistic activity together with radiotherapy in glioblastoma.
W. Wick, T. Gorlia, M. Bent, C. Vecht, J. Steuve, A. Brandes, M. Plattén, M. Kosch, M. Hegi, B. Lhermitte, V. Golfinopoulos, M. Campone, J. Frenel, M. Taphoorn, G. Pesce, P. Roth   +15 more
semanticscholar   +1 more source

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Journal of Clinical Oncology, 2005
PURPOSE Mantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1 messenger RNA. This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that ...
T. Witzig, S. Geyer, I. Ghobrial, D. Inwards, R. Fonseca, Paul J. Kurtin, S. Ansell, R. Luyun, P. Flynn, R. Morton, S. Dakhil, H. Gross, S. Kaufmann   +12 more
semanticscholar   +1 more source

Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients.

Journal of Clinical Oncology, 2009
5039 Background: Combined mTOR and VEGF blockade is a potentially promising and rational strategy for the treatment of advanced RCC. We previously reported the phase I safety and efficacy results of CCI 779 (C) +bevacizumab (B) n RTKI naïve stage IV RCC ...
J. Merchan, H. Pitot, R. Qin, G. Liu, T. Fitch, J. Picus, W. Maples, C. Erlichman   +7 more
semanticscholar   +1 more source

A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

Japanese Journal of Clinical Oncology, 2010
OBJECTIVE Temsirolimus (CCI-779) is a novel inhibitor of the mammalian target of rapamycin. This Phase 1 study was aimed at investigating the maximum-tolerated dose, toxicity, pharmacokinetics and antitumor activity in Japanese patients with advanced ...
Y. Fujisaka, Y. Yamada, N. Yamamoto, A. Horiike, T. Tamura   +4 more
semanticscholar   +1 more source

Rapamycin Ester Analog CCI-779/Temsirolimus Alleviates Tau Pathology and Improves Motor Deficit in Mutant Tau Transgenic Mice

Journal of Alzheimer's Disease, 2015
C. Frédérick, K. Ando, K. Leroy, Céline Héraud, V. Suain, L. Buée, J. Brion   +6 more
semanticscholar   +1 more source